J Costello

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Table S1 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance

  2025-11-25

• Supplementary Table S2 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance

  2025-11-25

• Supplementary Figures S1-S17 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance

  2025-11-25

• Supplementary Methods S1 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance

  2025-11-25

• EXTH-77. An AI-engineered bioPROTAC reverses immortality of <i>TERT</i> promoter mutant tumors

  Neuro-Oncology · 2025-11-01

• EXTH-52. Spatially Resolved Antigenic Landscapes In Low-grade Glioma Reveal Targets For Personalized Immunotherapy

  Neuro-Oncology · 2025-11-01

• EPCO-23. MOLECULAR CHARACTERIZATION OF CRISPROFF EPIGENETIC EDITOR ACTIVITY REVEALS MUTANT ALLELE-SPECIFIC <i>TERT</i> REPRESSION IN GLIOBLASTOMA

  Neuro-Oncology · 2025-11-01

• TMIC-110. Role of LRRC25 in local and systemic immunosuppression and its reversal

  Neuro-Oncology · 2025-11-01

• RBIO-10. Targeting telomere maintenance sensitizes group 3 medulloblastomas to ionizing radiation

  Neuro-Oncology · 2025-11-01

• 3D spatial sampling to quantify morphologic heterogeneity in isocitrate dehydrogenase-wildtype glioblastoma

  Journal of Neuropathology & Experimental Neurology · 2025-09-03 · 1 citations

• Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomasPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-07-15 · 2 citations

• The immortality mechanism of TERT promoter mutant cancers is self-reinforcing and reversible

  Molecular Cell · 2025-06-01 · 4 citations

• Abstract 3894: Three-dimensional whole tumor genomic analysis redefine intratumor heterogeneity of gliomas, with implications for early tumorigenesis

  Cancer Research · 2025-04-21

• Abstract 4250: Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens across cancers

  Cancer Research · 2025-04-21 · 1 citations

• Spatial 3D genome organization reveals intratumor heterogeneity in primary glioblastoma samples

  Science Advances · 2025-03-12 · 11 citations

• Tumour-wide RNA splicing aberrations generate actionable public neoantigens

  Nature · 2025-02-19 · 64 citations

• Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival

  Neuro-Oncology Advances · 2025-01-01 · 1 citations

• IL-1 IDHWT GLIOBLASTOMA LONGITUDINAL MOLECULAR EVOLUTION

  Neuro-Oncology Advances · 2024-11-29

• PATH-30. CLINICAL OUTCOMES AND PREDICTIVE BIOMARKERS FOR IDH-WILDTYPE GLIOBLASTOMAS DEVELOPING HYPERMUTATION FOLLOWING TEMOZOLOMIDE TREATMENT

  Neuro-Oncology · 2024-11-01

• 155 Sub-clonal antigenic heterogeneity mediates immune evasion in low-grade gliomas

  Regular and Young Investigator Award Abstracts · 2024-11-01